Skip to main content

Market Overview

GenMark, T2 And Accelerate Diagnostics Impress Analysts At Microbiology Forum

GenMark, T2 And Accelerate Diagnostics Impress Analysts At Microbiology Forum

Canaccord Genuity provided some remarks on three companies after attending the "American Society for Microbiology" forum. According to the report published Monday, the Canaccord Genuity analysts are positive on GenMark Diagnostics, Inc (NASDAQ: GNMK) and T2 Biosystems Inc (NASDAQ: TTOO), and they expect Accelerate Diagnostics Inc (NASDAQ: AXDX) to remain a key player to follow in 2016–2017.

Related Link: NantHealth Uses The Cloud To Offer Value, Drive Earnings

The analysts noted it is possible to see "additional consolidation as upstart growth companies enter new verticals, or eat into the shares of the incumbents," despite a strong competition in infectious disease. Strong traffic was noticed in booths of all three companies during the exhibition.

At Time Of Writing...

  • Accelerate was down 4.41 percent at $14.30 on the day.
  • T2 was down 2.47 percent at $8.29.
  • GenMark was down 3.95 percent at $8.02.

Latest Ratings for AXDX

Oct 2020BTIGInitiates Coverage OnNeutral
Aug 2020Piper SandlerMaintainsOverweight
Sep 2019JP MorganDowngradesNeutralUnderweight

View More Analyst Ratings for AXDX
View the Latest Analyst Ratings


Related Articles (GNMK + AXDX)

View Comments and Join the Discussion!

Posted-In: Analyst Color Biotech Long Ideas News Health Care Events Analyst Ratings Movers

Latest Ratings

NIUDaiwa CapitalInitiates Coverage On41.5
QMCONorthland Capital MarketsInitiates Coverage On12.0
IBKRJefferiesInitiates Coverage On89.0
MRETFTD SecuritiesDowngrades18.5
SWKSGoldman SachsDowngrades135.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at